Sensorion Overview
Pro stress-test →Sensorion is a pioneering clinical-stage and gene therapy biotech company which specializes in the development of novel therapies to treat, prevent and restore within the field of hearing loss disorders. This addresses hearing loss disorders, a significant global unmet medical need.
Strategic Profile
Pro stress-test →The company has built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and mechanisms of action for drug candidates. Recent strategic backing from Sanofi ($20 million) alongside €60 million total financing demonstrates confidence in the pipeline focused on genetic medicine.
Competitive Landscape
Pro stress-test →Sensorion competes in rare genetic hearing loss therapy space against larger diversified pharma companies (Novartis, Roche) and emerging gene therapy platforms. Strategic collaboration with Institut Pasteur provides differentiation in genetic hearing loss. Limited direct pure-play competitors in this specific niche.
Industry Context
Sensorion operates in Biotechnology / Clinical-Stage Gene Therapy.
Key facts
Founded: 2009 · Headquarters: Montpellier, France · Employees: 63 · Revenue: $6.65M (2024) · Market cap: $178M